Tags

Type your tag names separated by a space and hit enter

Population impact of Vi capsular polysaccharide vaccine.
Expert Rev Vaccines. 2010 May; 9(5):485-96.ER

Abstract

Development of a safe and efficacious vaccine against typhoid fever has been the mainstay of enteric vaccinology since production of the first parenteral whole-cell typhoid vaccine in 1896. The new-generation Vi polysaccharide single-dose injectable typhoid vaccine developed in the 1980s is widely used in countries where it is locally produced, such as China, and in travelers from industrialized countries to typhoid-endemic settings. However, Vi vaccine use is limited to private practice at a small scale by residents of high-burden countries such as India, Pakistan and Bangladesh. Recognition of the public health importance of typhoid fever prevention has significantly increased due to the emergence of antimicrobial-resistant strains of Salmonella enterica serovar Typhi in recent years. Recent evidence of herd protection conferred by the Vi vaccine has highlighted the significance of the vaccine's effects beyond the vaccinated population. The large-scale use of this vaccine can yield protective benefits to a larger population and can reduce the epidemiologic and economic burden of typhoid fever in endemic countries.

Authors+Show Affiliations

International Vaccine Institute, Seoul, 151-919, Republic of Korea.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20450323

Citation

Khan, M Imran, et al. "Population Impact of Vi Capsular Polysaccharide Vaccine." Expert Review of Vaccines, vol. 9, no. 5, 2010, pp. 485-96.
Khan MI, Ochiai RL, Clemens JD. Population impact of Vi capsular polysaccharide vaccine. Expert Rev Vaccines. 2010;9(5):485-96.
Khan, M. I., Ochiai, R. L., & Clemens, J. D. (2010). Population impact of Vi capsular polysaccharide vaccine. Expert Review of Vaccines, 9(5), 485-96. https://doi.org/10.1586/erv.10.43
Khan MI, Ochiai RL, Clemens JD. Population Impact of Vi Capsular Polysaccharide Vaccine. Expert Rev Vaccines. 2010;9(5):485-96. PubMed PMID: 20450323.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Population impact of Vi capsular polysaccharide vaccine. AU - Khan,M Imran, AU - Ochiai,R Leon, AU - Clemens,John D, PY - 2010/5/11/entrez PY - 2010/5/11/pubmed PY - 2010/8/7/medline SP - 485 EP - 96 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 9 IS - 5 N2 - Development of a safe and efficacious vaccine against typhoid fever has been the mainstay of enteric vaccinology since production of the first parenteral whole-cell typhoid vaccine in 1896. The new-generation Vi polysaccharide single-dose injectable typhoid vaccine developed in the 1980s is widely used in countries where it is locally produced, such as China, and in travelers from industrialized countries to typhoid-endemic settings. However, Vi vaccine use is limited to private practice at a small scale by residents of high-burden countries such as India, Pakistan and Bangladesh. Recognition of the public health importance of typhoid fever prevention has significantly increased due to the emergence of antimicrobial-resistant strains of Salmonella enterica serovar Typhi in recent years. Recent evidence of herd protection conferred by the Vi vaccine has highlighted the significance of the vaccine's effects beyond the vaccinated population. The large-scale use of this vaccine can yield protective benefits to a larger population and can reduce the epidemiologic and economic burden of typhoid fever in endemic countries. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/20450323/Population_impact_of_Vi_capsular_polysaccharide_vaccine_ DB - PRIME DP - Unbound Medicine ER -